We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“There is a lot of confusing evidence on the use of beta-blockers, so we've tried to clarify as much as we can.”
“Continued emphasis should be given to preoperative clinical risk stratification, with noninvasive testing reserved for those patients in whom a substantial change in medical management would be anticipated based on results of testing. Pharmacologic therapy holds more promise than coronary revascularization for the reduction of major adverse perioperative cardiac events that might complicate noncardiac surgery.”
“The perioperative community is stuck between a rock and a hard place. On one hand, there are now discredited data. On the other hand, credible data employ a peri-operative beta-blocker regimen that is not representative of clinical practice.”
No takes yet. Share an insight, caveat, or question.
Fleisher et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: